NCT00730821已完成1 期
A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 4
- 主要终点
- The primary endpoint of this trial is the safety of the combination of BIBW 2992/BIBF 1120 when administered concomitantly, and this is assessed by the dose limiting toxicity
研究概览
简要总结
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule.
Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with confirmed diagnosis of advanced, non-resectable and/or metastatic solid tumors, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment.
- •Age 18 years or older.
- •Life expectancy of at least three (3) months.
- •Written informed consent that is consistent with ICH-GCP guidelines.
- •Eastern Cooperative Oncology Group performance score 0, 1or
- •Patients recovered from any therapy-related toxicities from previous chemo-,hormone-, immuno-, or radiotherapies to CTC <= Grade
- •Patients must have recovered from previous surgery.
排除标准
- •Active infectious disease.
- •Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
- •Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
- •Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least four (4) weeks, no history of cerebral edema or bleeding in the past four (4) weeks and no requirement for steroids or anti-epileptic therapy.
- •Cardiac left ventricular function with resting ejection fraction <50%.
- •Absolute neutrophil count (ANC) less than 1500/mm
- •Platelet count less than 100,000/mm
- •Bilirubin greater than 1.5 mg/dl (>26 ¿mol /L, SI unit equivalent).
- •Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than two and a half times the upper limit of normal (2.5 X ULN ).
- •Serum creatinine greater than 1.5 mg/dl (>132 ¿mol/L, SI unit equivalent).
- •Women and men who are sexually active and unwilling to use a medically acceptable method of contraception.
- •Pregnancy or breast-feeding.
- •Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (including LHRH agonists, megestrol acetate, or other hormones taken for breast cancer or prostate cancer); participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with bisphosphonates is allowed.
- •Treatment with an EGFR- or HER2 inhibiting drug within the past 4 weeks before start of therapy or concomitantly with this study (2 weeks for trastuzumab).
- •Patients unable to comply with the protocol.
- •Active alcohol or drug abuse.
- •Patients who require therapeutic anticoagulation or antiplatelet therapy [except treatment with Aspirin (Acetylsalicylic Acid)].
- •Patients with history of haemorrhagic or thrombotic events (including transient ischemic attacks) in the past 12 months. Known inherited predisposition to bleeding or thrombosis.
研究组 & 干预措施
1
Experimental
干预措施: BIBW 2992 (Drug)
1
Experimental
干预措施: BIBF 1120 (Drug)
结局指标
主要结局
The primary endpoint of this trial is the safety of the combination of BIBW 2992/BIBF 1120 when administered concomitantly, and this is assessed by the dose limiting toxicity
时间窗: Until undue toxicity or progressive disease.
次要结局
- Pharmacokinetics, Objective tumor response.(Until undue toxicity or progressive disease.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02182232Boehringer Ingelheim33
已完成
1 期
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.NeoplasmsNCT00998296Boehringer Ingelheim70
已完成
1 期
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological MalignanciesGenital Neoplasms, FemaleNCT02182245Boehringer Ingelheim22
已完成
1 期
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or GefitinibCarcinoma, Non-Small-Cell LungNCT00993499Boehringer Ingelheim44
已完成
1 期
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsNeoplasmsNCT02171637Boehringer Ingelheim38